Bluebird's Zynteglo trials set to resume, putting gene therapy back on flight path to FDA filing

Bluebird Bio's beta-thalassemia gene therapy Zynteglo has struggled to spread its wings, and a recent clinical pause certainly didn't help. But with studies on several bluebird drugs set to resume, Zynteglo could be looking at clearer skies ahead.